The US economy is gaining traction despite concerns over the spread of the new Delta variant of COVID-19. On Friday, the US Labor Department released the much-awaited Nonfarm Payrolls report, which showed that companies hired the most workers in nearly a year last month and continued to increase salaries.
This is a great boost for the economy, as it might show the greatest annual growth in over four decades.
The unemployment rate fell to a 16-month low of 5.4%, and more people went back into the labor force. The report follows GDP data from last week, according to which the US economy returned to pre-pandemic levels, even though the growth fell short of expectations. Nonfarm payrolls rose 943,000 jobs in July, the largest gain since August last year and more than anticipated. Data for May and June were revised upward to reflect 119,000 more jobs created than previously reported.
Brian Bethune, professor of practice at Boston College in Boston, told Reuters:
“We are charting new economic expansion territory in the third quarter. The overall momentum of the recovery continues to build.”
Meanwhile, the stock market indexes continue to fluctuate near their all-time highs. This is really a great time to invest in penny stocks as companies are ramping up their operations following the pandemic.
OTC MARKETS THE PLACE TO BE
There are many good OTC stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading hot OTC stocks is finding momentum BEFORE it happens and then be patient.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of OTC stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 trending OTC stocks gaining momentum.
In this article, we look at 4 penny stocks to watch that will greatly reward patient investors. They are Therapeutic Solutions International, Inc (OTCPK: TSOI), Regen BioPharma, Inc (OTCPK: RGBP), VitanaX, Inc (OTCPK: VITX), and Ascent Solar Technologies, Inc (OTCPK: ASTI).
OTC Stocks to Watch #1 TSOI
Therapeutic Solutions International, Inc. has shown signs of revival during the first week of August after several months of correction. On Thursday, August 5, the share price surged over 100% from $0.038 to $0.08, which is the highest level since the beginning of May. At one point, volume surged above 1.5 million shares. The price eventually corrected to the current level of $0.061. TSOI peaked in mid-February at about $0.15. Prior to that, the OTC stock used to fluctuate near one cent for years.
The sudden surge earlier this month was driven by a major announcement. Specifically, TSOI said that the Food and Drug Administration (FDA) had given it the green light to start a Phase III pivotal trial for registration of its JadiCell™ universal donor stem cell as a treatment for COVID-associated lung failure.
The company said that it had previously demonstrated the superior activity of JadiCell to other types of stem cells, including bone marrow, adipose, cord blood, and placenta. TSOI’s JadiCell was reportedly shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo-controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85, the survival rate was 91%.
The company’s director Dr. Thomas E. Ichim said:
“FDA clearance to initiate a Phase III clinical trial means we are at the last phase of development before commercially selling the product. This positions us in a highly exclusive place in that to our knowledge no other cells have this potent ability to concurrently suppress inflammation while restoring function of tissue damaged by SAR-CoV-2.”
Famela Ramos, VP of TSOI’s Business Development, said that despite the massive vaccination program, there were many people refusing them, plus there are also patients in whom vaccines had failed to induce appropriate immunity. Once COVID-19 initiates its pathological cascade leading to lung failure, no therapies exist until now to address this population.
The FDA approval for the last step of treatment review is a big deal for TSOI, and we’re definitely bullish on this OTC stock. Besides JadiCell, TSOI is working on the treatment of neurological diseases. It is also producing high-quality nutraceuticals like NanoStilbene as well as provides its StemVacs, which is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein-based vaccines.
OTC Stocks to Watch #2 RGBP
Our subscribers are familiar with Regen BioPharma, Inc, which we have high expectations of considering that it stays on a pile of patents. The OTC stock peaked in April at almost six cents after surging by over 2,300% in a few days. It has corrected since then, but now it seems ready to challenge the year-to-date high. The share price has gained over 71% during the last five days, trading close to $0.025, which is the highest level since April.
The OTC stock is still looking to become Pink Current and remove the “Delinquent SEC Reporting” symbol from OTC Markets. It may achieve this next week as it recently filed its quarterly and annual report with the SEC, which will give another support to the share price. Once it gets the Pink Current status soon, it may release at least one 8-K report, and many investors expect some merger news, although this is pure speculation at this point. In any case, the following days will be exciting and now is the best time to enter the market.
RGBP is focused on the immunology and immunotherapy space. At the moment, RGBP is focused on small molecule therapies for treating cancer and autoimmune disorders.
Besides this, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. Stem cells are special cells that can develop into any type of human cells, which opens new possibilities in therapeutics. The company produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.
Earlier this year, RGBP signed two deals with Oncology Pharma, a leader in oncology treatments. One deal focuses on treating pancreatic cancer, and the other one is for the treatment of colon cancer.
Investors expect that Oncology, Precigen, or another candidate will soon buy Regen.
With or without a merger, RGBP is a good stock to hold in your portfolio with a long-term target, as the company can monetize its patents and eventually reach NASDAQ someday.
OTC Stocks to Watch #3 VITX
VitanaX, Inc has shown some great moves this month, almost doubling its price since August 1. The company is working to become Pink Current, and this might come as a great opportunity for investors.
VITX peaked earlier this year at $0.025 and then corrected until the end of July. As it gets closer to the Pink Current status, VITX is ready to update the YTD high and gradually expand its business.
What we know today is that VITX is an international wellness company focusing on the development and manufacture of health-promoting products based on DNA analysis. The company provides comprehensive programs for greater well-being, fitness, and health by helping clients achieve the desired results and offering exercises that fit their body type.
This is a new business direction, as VITX was previously known as GH Capital Inc and primarily focused on services-prepackaged software.
In January, Vitana-X engaged with a law firm to apply for its FDA submission to gain approval to distribute its products in the US. Its patented micellization technology allows for pure products of plant nature, such as curcumin, hemp, omega 369, and vitamins B, C, D, and E in water-soluble form and the highest organic availability. Thus, Vitana-X products have an edge over competitors.
Outside the US, VITX has several product lines, including Immune-X, CBD Complex, CDE Complex, and Revival Energy.
In July, the company finally announced the preparations to enter the US market. The expected initial launch event in the US will take place in Florida in November of this year.
VITX CEO Alois Anichhofer said:
“We already know that the enthusiasm for our 100% natural products and our patents is strong. We are optimistic for a huge start in the US market. While there is still some work to do before we can start final talks with the American leaders by September. We are targeting Beauty, Health and Wellness, Lifestyle and DNA-Analytics – and look forward to conquering the hearts in MLM.”
While the multi-level marketing approach might not be the best one in the long term, VITX is poised to expand rapidly following the launch, considering the increasing demand for health products.
$VITX Due Diligence :
📌 Wellness company with CBD products and DNA analytics
📌 Low float only 1.3B
📌 NO dilution
📌 HUGE revenues – double digit million range !!!
📌 Over 30,000 sales agents worldwide !!
📌 Press release is on the way.
📌 80% Discount from HIGHTS! pic.twitter.com/I7GMX1qugp
— NarutOTC (@NarutOTC_) July 13, 2021
OTC Stocks to Watch #4 ASTI
Ascent Solar Technologies, Inc has been quite bullish during the last few days, gaining over 45% since the beginning of August and more than 110% since the start of July. The OTC stock hit a YTD high in mid-February at $0.073, but it quickly entered a correction phase that lasted for months. The share price bottomed out at the beginning of July at $0.013 and has almost doubled since then.
ASTI has some good fundamentals that prove the company is sustainable. The financial reports show that the $400+ million firm has been profitable last year for the first time in many years.
ASTI develops award-winning thin-film photovoltaic modules with substrate materials that are more flexible, versatile and rugged than traditional solar panels. Ascent Solar modules can be directly integrated into consumer products and off-grid applications, as well as aerospace and building integrated applications.
The company’s technology is in line with the current trends of renewable energy, and we think there is great value in this OTC stock.
On August 5, ASTI announced the signing of a new funding agreement with BD 1 Investment Holding, LLC, which is the investment holding arm of the German controlling shareholders of ASTI. Earlier this month, ASTI entered into a securities purchase agreement with BD 1 to sell 666.67 million shares of its Common Stock at the prevailing market price of $0.015 per share in exchange for new funding of $10 million.
ASTI CEO Victor Lee said:
“Despite the ongoing pandemic, Ascent’s team has shown great resiliency and perseverance in restarting operations and continuing to pursue our ambition to deliver innovative power solutions for everyone everywhere. The new funding will enable Ascent to execute our business plan to deliver long-term shareholder value by focusing on capacity ramp-up, technological improvement and sales development. We will continue to strengthen our balance sheet as we ramp up production to serve the Tier-1 specialty PV markets in conjunction with satisfying the future demand of TubeSolar AG.”
Indeed, this new funding agreement proves that controlling shareholders have great trust in the company following its restructuring and recapitalization effort undertaken in early 2020. ASTI is a great turnaround play at the moment with enormous potential.
THE FINAL NOTE
Today is a great opportunity to benefit from the stock market’s bullishness and invest in penny stocks with great potential during a reviving economy. Our job is to identify the best penny stock alerts with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio oriented at penny stocks.
All of the 4 penny stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever a penny stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.